Regeneron Pharmaceuticals Board of Directors Compensation and Salary

Regeneron Pharmaceuticals is an American biotechnology company, headquartered in Tarrytown, New York, United States. The company is listed on the NASDAQ with ticker name REGN . Leonard Schleifer is heading the company as the chief executive officer since 1988. The company is engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. They have more than 9,123 employees in 2020.

So, let’s see information on Regeneron Pharmaceuticals Board of Directors Compensation and Salary. 

Regeneron Pharmaceuticals Board of Directors Compensation and Salary 2020

Bonnie L. Bassler, Ph.D. – Former President of the American Society for Microbiology

This board member is the Former President of the American Society for Microbiology. This board member was paid total compensation US$709,999, including base salary (paid in cash) US$110,000, stock awards US$119,718 and option awards US$480,281.

Michael S. Brown, M.D. – member of the National Academy of Sciences

This board member is the member of the National Academy of Sciences. This board member was paid total compensation US$719,999, including base salary (paid in cash) US$120,000, stock awards US$119,718 and option awards US$480,281.

N. Anthony Coles, M.D.

This board member was paid total compensation US$704,999, including base salary (paid in cash) US$100,000, stock awards US$119,718, option awards US$480,281 and all other compensation US$5,0004.

Joseph L. Goldstein, M.D. – Boards of Trustees of The Rockefeller University

This board member is the Boards of Trustees of The Rockefeller University. This board member was paid total compensation US$709,999, including base salary (paid in cash) US$110,000, stock awards US$119,718 and option awards US$480,281.

Christine A. Poon – Former vice chairman and worldwide chairman of pharmaceuticals at Johnson & Johnson

This board member is the Former vice chairman and worldwide chairman of pharmaceuticals at Johnson & Johnson. This board member was paid total compensation US$719,999, including base salary (paid in cash) US$120,000, stock awards US$119,718 and option awards US$480,281.

Arthur F. Ryan – Former Chairman and Chief Executive Officer of Prudential Financial, Inc.

This board member is the Former Chairman and Chief Executive Officer of Prudential Financial, Inc. This board member was paid total compensation US$724,999, including base salary (paid in cash) US$120,000, stock awards US$119,718, option awards US$480,281 and all other compensation US$5,0004.

George L. Sing – Chief Executive Officer of Stemnion, Inc.

This board member is the Chief Executive Officer of Stemnion, Inc. This board member was paid total compensation US$120,000, including base salary (paid in cash) US$, stock awards US$119,718 and option awards US$480,281.

Marc Tessier-Lavigne, Ph.D.

This board member is the . This board member was paid total compensation US$719,999, including base salary (paid in cash) US$120,000, stock awards US$119,718 and option awards US$480,281.

P. Roy Vagelos, M.D. – President and Chief Executive Officer at Merck

This board member is the President and Chief Executive Officer at Merck. This board member was paid total compensation US$6,109,024, including base salary (paid in cash) US$0, stock awards US$1,199,988, option awards US$4,799,997 and all other compensation US$109,0395.

Huda Y. Zoghbi, M.D. – professor at the Departments of Molecular and Human Genetics at Baylor College of Medicine

This board member is the professor at the Departments of Molecular and Human Genetics at Baylor College of Medicine. This board member was paid total compensation US$709,999, including base salary (paid in cash) US$110,000, stock awards US$119,718 and option awards US$480,281.